Stockreport

TransCode Therapeutics Announces Publication of Study with Lead Therapeutic Candidate Revealing Mechanisms Behind Candidate’s Preclinical Efficacy Against Metastatic Cancer

TransCode Therapeutics, Inc.  (RNAZ) 
PDF BOSTON, Sept. 10, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RN [Read more]